NEW YORK (GenomeWeb) – Roche said today that its diagnostics revenues grew 5 percent year over year for the first quarter of 2018, driven by growth across the entire Dx division.

For the three months ended March 31, the Swiss pharmaceutical and diagnostics company reported overall revenues of CHF 13.58 billion ($13.85 billion), up 5 percent from CHF 12.94 billion in Q1 2017.

In diagnostics, Roche reported revenues of CHF 2.91 billion, up from CHF 2.77 billion in 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.